Vanta Bioscience Share Price

Vanta Bioscience Limited (VBS) was originally incorporated as a Private Limited Company on 29th April 2016 and was converted into a Public Limited Company with effect from 17th March 2017.VBS is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, Company provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. It also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.The Company is established as a center of excellence for GLP toxicology and safety assessment offering services in India and across the globe. One of the major services of VBS is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms.The Company purchased preclinical CRO facility at Gummidipundi, Chennai from Kemin Industries South Asia Private Limited which was named as Vanta Bioscience (a toxicology division and commenced commercial activities in April, 2017. VBS has state of the art facilities and infrastructure necessary for conduct of all kind of toxicology studies for Chemicals, Pharmaceuticals, Cosmetics, Agrochemicals like Pesticides, Insecticides, Excipients, Novel Feed Additives. In addition, the Company conducts preclinical proofofconcept (PoC) studies for novel pharmaceuticals and products intended for new indications in variety of animal models of human diseases through a robust process of validation. In September 2017, the Company came up with a Public Issue of 15,12,000 Equity Shares by raising money from public aggregating to Rs 7.56 Crore.In 201819, Vanta Clinical Research Limited and Vayam Research Solutions Limited became the subsidiaries of the Company.